Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nutricia Research
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven CRC stage IIB, III or IV or histologically or cytologically proven NSCLC stage III or IV
Eligible and scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment with a planned duration of at least 12 weeks
Performance status Eastern Cooperative Oncology Group (ECOG) score 0 or 1
Age ≥ 18 years
Written informed consent
You may not be if
Scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment starting ≤4 days after randomization
Received radiotherapy within 2 months prior to the study
Weight loss \>10% in the last 6 months
Body Mass Index \< 20.0 kg/m2
Life expectancy \< 3 months
Prescription of oral nutritional supplementation (ONS) before start of first line treatment based on hospital's standard practice
Presence of ileostoma or ileal pouch
Contra-indications to oral feeding, high protein nutrition or to the test product (including galactosaemia) in the opinion of the investigator
Known pregnancy or lactation
Current alcohol or drug abuse in the opinion of the investigator
Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
Clareo Health | Protein Intake in Patients With Colorectal or Lung Cancer When Receiving a Nutritional Supplement
